519 related articles for article (PubMed ID: 18495732)
21. Differences in synovial tissue infiltrates between anti-cyclic citrullinated peptide-positive rheumatoid arthritis and anti-cyclic citrullinated peptide-negative rheumatoid arthritis.
van Oosterhout M; Bajema I; Levarht EW; Toes RE; Huizinga TW; van Laar JM
Arthritis Rheum; 2008 Jan; 58(1):53-60. PubMed ID: 18163491
[TBL] [Abstract][Full Text] [Related]
22. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
Alivernini S; Tolusso B; Petricca L; Bui L; Di Sante G; Peluso G; Benvenuto R; Fedele AL; Federico F; Ferraccioli G; Gremese E
Ann Rheum Dis; 2017 Jul; 76(7):1228-1236. PubMed ID: 28119289
[TBL] [Abstract][Full Text] [Related]
23. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
Park MC; Chung SJ; Park YB; Lee SK
Scand J Rheumatol; 2008; 37(3):173-8. PubMed ID: 18465450
[TBL] [Abstract][Full Text] [Related]
24. Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis.
Yamada H; Nakashima Y; Okazaki K; Mawatari T; Fukushi JI; Kaibara N; Hori A; Iwamoto Y; Yoshikai Y
Ann Rheum Dis; 2008 Sep; 67(9):1299-304. PubMed ID: 18063670
[TBL] [Abstract][Full Text] [Related]
25. Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry.
Hetland ML; Lindegaard HM; Hansen A; Pødenphant J; Unkerskov J; Ringsdal VS; Østergaard M; Tarp U
Ann Rheum Dis; 2008 Jul; 67(7):1023-6. PubMed ID: 18272669
[TBL] [Abstract][Full Text] [Related]
26. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis.
Ulfgren AK; Andersson U; Engström M; Klareskog L; Maini RN; Taylor PC
Arthritis Rheum; 2000 Nov; 43(11):2391-6. PubMed ID: 11083259
[TBL] [Abstract][Full Text] [Related]
27. Assessment of anti-TNF-alpha efficacy in rheumatoid arthritis: is 3 months sufficient?
Pocock JM; Vasconcelos JC; Ostör AJ
Rheumatology (Oxford); 2008 Jul; 47(7):1073-6. PubMed ID: 18503089
[TBL] [Abstract][Full Text] [Related]
28. Tumour necrosis factor blockade increases lymphangiogenesis in murine and human arthritic joints.
Polzer K; Baeten D; Soleiman A; Distler J; Gerlag DM; Tak PP; Schett G; Zwerina J
Ann Rheum Dis; 2008 Nov; 67(11):1610-6. PubMed ID: 18174217
[TBL] [Abstract][Full Text] [Related]
29. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register.
Karlsson JA; Kristensen LE; Kapetanovic MC; Gülfe A; Saxne T; Geborek P
Rheumatology (Oxford); 2008 Apr; 47(4):507-13. PubMed ID: 18304941
[TBL] [Abstract][Full Text] [Related]
30. Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate.
Parker A; Izmailova ES; Narang J; Badola S; Le T; Roubenoff R; Ginsburg GS; Maier A; Coblyn JS; Shadick NA; Weinblatt ME
J Rheumatol; 2007 Sep; 34(9):1817-22. PubMed ID: 17696278
[TBL] [Abstract][Full Text] [Related]
31. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis.
Radovits BJ; Kievit W; Fransen J; van de Laar MA; Jansen TL; van Riel PL; Laan RF
Ann Rheum Dis; 2009 Sep; 68(9):1470-3. PubMed ID: 19015210
[TBL] [Abstract][Full Text] [Related]
32. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.
Genevay S; Finckh A; Ciurea A; Chamot AM; Kyburz D; Gabay C;
Arthritis Rheum; 2007 May; 57(4):679-85. PubMed ID: 17471545
[TBL] [Abstract][Full Text] [Related]
33. Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis.
Mattey DL; Brownfield A; Dawes PT
J Rheumatol; 2009 Jun; 36(6):1180-7. PubMed ID: 19447930
[TBL] [Abstract][Full Text] [Related]
34. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience.
Jois RN; Masding A; Somerville M; Gaffney K; Scott DG
Rheumatology (Oxford); 2007 Jun; 46(6):980-2. PubMed ID: 17384180
[TBL] [Abstract][Full Text] [Related]
35. Detection, identification and in vivo treatment responsiveness of bone morphogenetic protein (BMP)-activated cell populations in the synovium of patients with rheumatoid arthritis.
Verschueren PC; Lories RJ; Daans M; Théate I; Durez P; Westhovens R; Luyten FP
Ann Rheum Dis; 2009 Jan; 68(1):117-23. PubMed ID: 18276742
[TBL] [Abstract][Full Text] [Related]
36. Alterations of the synovial T cell repertoire in anti-citrullinated protein antibody-positive rheumatoid arthritis.
Cantaert T; Brouard S; Thurlings RM; Pallier A; Salinas GF; Braud C; Klarenbeek PL; de Vries N; Zhang Y; Soulillou JP; Tak PP; Baeten D
Arthritis Rheum; 2009 Jul; 60(7):1944-56. PubMed ID: 19565497
[TBL] [Abstract][Full Text] [Related]
37. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis.
Haringman JJ; Gerlag DM; Zwinderman AH; Smeets TJ; Kraan MC; Baeten D; McInnes IB; Bresnihan B; Tak PP
Ann Rheum Dis; 2005 Jun; 64(6):834-8. PubMed ID: 15576415
[TBL] [Abstract][Full Text] [Related]
38. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis.
McGonagle D; Tan AL; Madden J; Taylor L; Emery P
Rheumatology (Oxford); 2008 Jun; 47(6):865-7. PubMed ID: 18390581
[TBL] [Abstract][Full Text] [Related]
39. Missed opportunities in the treatment of elderly patients with rheumatoid arthritis.
Radovits BJ; Fransen J; Eijsbouts A; van Riel PL; Laan RF
Rheumatology (Oxford); 2009 Aug; 48(8):906-10. PubMed ID: 19478038
[TBL] [Abstract][Full Text] [Related]
40. T cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4Ig but is successfully treated by interleukin-17 neutralization.
Koenders MI; Marijnissen RJ; Joosten LA; Abdollahi-Roodsaz S; Di Padova FE; van de Loo FA; Dulos J; van den Berg WB; Boots AM
Arthritis Rheum; 2012 Jun; 64(6):1762-70. PubMed ID: 22213107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
